Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Mamm Genome. 2023 Jun;34(2):312-322. doi: 10.1007/s00335-023-09978-z. Epub 2023 Feb 7.
Dilated cardiomyopathy (DCM) is a group of heart muscle diseases that often lead to heart failure, with more than 50 causative genes have being linked to DCM. The heterogenous nature of the inherited DCMs suggest the need of precision medicine. Consistent with this emerging concept, transcriptome studies in human patients with DCM indicated distinct molecular signature for DCMs of different genetic etiology. To facilitate this line of research, we reviewed the status of transcriptome studies of inherited DCMs by focusing on three predominant DCM causative genes, TTN, LMNA, and BAG3. Besides studies in human patients, we summarized transcriptomic analysis of these inherited DCMs in a variety of model systems ranging from iPSCs to rodents and zebrafish. We concluded that the RNA-seq technology is a powerful genomic tool that has already led to the discovery of new modifying genes, signaling pathways, and related therapeutic avenues. We also pointed out that both temporal (different pathological stages) and spatial (different cell types) information need to be considered for future transcriptome studies. While an important bottle neck is the low throughput in experimentally testing differentially expressed genes, new technologies in efficient animal models such as zebrafish starts to be developed. It is anticipated that the RNA-seq technology will continue to uncover both unique and common pathological events, aiding the development of precision medicine for inherited DCMs.
扩张型心肌病(DCM)是一组心肌疾病,常导致心力衰竭,已有 50 多个致病基因与 DCM 相关。遗传性 DCM 的异质性表明需要精准医疗。与这一新兴概念一致,对患有 DCM 的人类患者的转录组研究表明,不同遗传病因的 DCM 具有不同的分子特征。为了促进这一研究,我们重点关注三个主要的 DCM 致病基因 TTN、LMNA 和 BAG3,综述了遗传性 DCM 的转录组研究现状。除了对人类患者的研究外,我们还总结了这些遗传性 DCM 在各种模型系统(从 iPSCs 到啮齿动物和斑马鱼)中的转录组分析。我们得出结论,RNA-seq 技术是一种强大的基因组工具,已经发现了新的修饰基因、信号通路和相关的治疗途径。我们还指出,未来的转录组研究需要同时考虑时间(不同的病理阶段)和空间(不同的细胞类型)信息。虽然一个重要的瓶颈是在实验中测试差异表达基因的低通量,但在斑马鱼等高效动物模型中开发新技术开始得到重视。预计 RNA-seq 技术将继续揭示独特和共同的病理事件,为遗传性 DCM 的精准医疗发展提供帮助。